Jonathan Ks. Goh

Jonathan Ks. Goh

Auto-generated profile, based on publicly available information

Jonathan Ks. Goh

Royal Victorian Eye and Ear Hospital, 32 Gisborne St, East Melbourne, Victoria, 3002, Australia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in Ophthalmology
Verified
Journal Article
Closed access
ZWZhichao Wu
Zhichao Wu
CLChi Luu
Chi Luu
LALauren N. Ayton
Lauren N. Ayton
JGJonathan K. Goh
Jonathan K. Goh
LLLucia M. Lucci
Lucia M. Lucci
RGRobyn Guymer
Robyn Guymer

22 January 2022 in American Journal of Ophthalmology Case Reports
Verified
Journal Article
Open access
ZCZelia K. Chiu
Zelia K. Chiu
JGJonathan Ks. Goh
Jonathan Ks. Goh
CLCecilia Ling
Cecilia Ling
MLMing-Lee Lin
Ming-Lee Lin
AHAnthony J. Hall
Anthony J. Hall
Four cases of ibrutinib-related uveitis are presented, which are to the best of our knowledge the first in the literature. Possible mechanisms of ibrutinib-mediated uveitis are explored. Case 1 is a 60-year-old female who had been stable on 1 year of ibrutinib for chronic lymphocytic leukaemia. She was diagnosed with ibrutinib-related uveitis, which responded well to topical steroids. Case 2 is a 63-year-old male diagnosed with uveitis after 2 years of ibrutinib treatment for chronic lymphocytic leukaemia. He responded well to topical and oral steroids; however, he continued to have uveitis relapses after weaning steroids. Case 3 is a 69-year-old male diagnosed with uveitis after 18 months of ibrutinib treatment. He was trialed on topical and intravenous steroids, and restarted ibrutinib without worsening of symptoms. Case 4 is a 66-year-old female who developed uveitis after being stable on ibrutinib for 3 years. She responded well to topical steroids. Inflammatory complications of tyrosine kinase inhibitors are well described. While ibrutinib, and other kinase inhibitors, are generally well-tolerated, there are increasing reports of ocular toxicities, including uveitis. It is recommended to monitor patients for potential ocular adverse effects and facilitate rapid ophthalmologic assessment.